Skip to the beginning of the images gallery

Irinotecan hydrochloride - 98%, high purity , CAS No.100286-90-6

5 Citations

≥98%

CAS#: 100286-90-6
Formula: C₃₃H₃₈N₄O₆ · HCl
Molecular Weight: 623.14
PubChem CID: 74990
PubChem SID: 488185009

Item Number

I102602

Grouped product items
SKU	Size	Availability	Price
I102602-50mg	50mg	In stock	$32.90
I102602-100mg	100mg	In stock	$47.90
I102602-250mg	250mg	In stock	$83.90
I102602-1g	1g	In stock	$234.90

Potent DNA topoisomerase I inhibitor

View related series

alkaloid Antitumor Research Reagents Autophagy Cell Cycle/DNA Damage Quinoline Alkaloids Topoisomerase

Basic Description

Synonyms	Campto \| DTXSID6045953 \| U 101440E \| UNII-06X131E4OE \| Camptosar \| Camptothecin 11 \| Camptothecin 11 hydrochloride \| CHEBI:5971 \| CPT-11 \| Irinotecan Hcl \| 06X131E4OE \| Irinotecan (hydrochloride) \| Topotecin \| CPT 11
Specifications & Purity	≥98%
Biochemical and Physiological Mechanisms	Irinotecan is a prodrug, which is converted to 7-ethyl-10-hydroxycamptothecin (SN-38), an effective inhibitor of DNA topoisomerase I, under the action of tissue carboxylesterase. The effect of UDP glucuronidase can be terminated by glucuronization. Irinot
Storage Temp	Store at -20°C
Shipped In	Ice chest + Ice pads
Note	Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description	Irinotecan hydrochloride has been used: • in combination with 5-fluorouracil for screening growth inhibitory functionality in MDA-MB-231 breast cancer cells. • in chemosensitivity screening of high-grade appendiceal (HGA) and low-grade appendiceal (LGA) organoids. • as a chemotherapeutic agent in the cytotoxicity studies in combination with heat shock proteins inhibitors (HPSC1) in HT29 colon cancer cells.

Associated Targets(Human)

GLA Tclin Alpha-galactosidase A (5444 Activities)

Discover Target: GLA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GBA1 Tclin Beta-glucocerebrosidase (14647 Activities)

Discover Target: GBA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GAA Tclin Lysosomal alpha-glucosidase (35701 Activities)

Discover Target: GAA

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ALDH1A1 Tchem Aldehyde dehydrogenase 1A1 (77053 Activities)

Discover Target: ALDH1A1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A498 (42825 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ACHN (49357 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CAKI-1 (44928 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CCRF-CEM (65223 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

COLO 205 (50209 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DLD-1 (17511 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DMS-273 (14108 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DU-145 (51482 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HL-60 (67320 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HT-29 (80576 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

K562 (73714 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

KM12 (47707 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

M14 (47487 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MCF7 (126967 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MOLT-4 (49676 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OVCAR-3 (48710 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OVCAR-4 (44535 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OVCAR-5 (45555 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

OVCAR-8 (47708 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PC-3 (62116 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Raji (5516 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPMI-8226 (44974 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RXF 393 (41971 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SF-295 (48000 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-MEL-2 (46422 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-MEL-28 (48833 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-MEL-5 (47095 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SK-OV-3 (52876 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SN12C (47755 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SNB-19 (46794 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TK-10 (45540 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

U-251 (51189 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

UACC-257 (46019 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

UACC-62 (47335 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

UO-31 (46270 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

XF498 (12972 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

786-0 (47912 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

A549 (127892 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NCI/ADR-RES (33767 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

T47D (39041 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

EKVX (44102 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NCI-H322M (45589 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HCC 2998 (41480 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HCT-116 (91556 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HOP-18 (11577 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

HOP-92 (41141 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Associated Targets(non-human)

Cruzipain (33337 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mus musculus (284745 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

P388/ADR (1216 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GCN5 Histone acetyltransferase GCN5 (89 Activities)

Discover Target: GCN5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FTL Ferritin light chain (43324 Activities)

Discover Target: FTL

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Names and Identifiers

Pubchem Sid	488185009
Pubchem Sid Url	https://pubchem.ncbi.nlm.nih.gov/substance/488185009
IUPAC Name	[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride
INCHI	InChI=1S/C33H38N4O6.ClH/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2;/h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3;1H/t33-;/m0./s1
InChi Key	GURKHSYORGJETM-WAQYZQTGSA-N
Canonical SMILES	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl
Isomeric SMILES	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl
WGK Germany	3
PubChem CID	74990
Molecular Weight	623.14

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

21 results found

Lot Number	Certificate Type	Date	Item
H2405484	Certificate of Analysis	Jul 01, 2024	I102602
L2315309	Certificate of Analysis	Nov 27, 2023	I102602
L2315308	Certificate of Analysis	Nov 27, 2023	I102602
G2326727	Certificate of Analysis	Jul 04, 2023	I102602
G2326737	Certificate of Analysis	Jul 04, 2023	I102602
G2326736	Certificate of Analysis	Jul 04, 2023	I102602
G2326734	Certificate of Analysis	Jul 04, 2023	I102602
G2326731	Certificate of Analysis	Jul 04, 2023	I102602
G2326725	Certificate of Analysis	Jul 04, 2023	I102602
B2302773	Certificate of Analysis	Nov 14, 2022	I102602
B2302870	Certificate of Analysis	Nov 14, 2022	I102602
B2302862	Certificate of Analysis	Nov 14, 2022	I102602
B2302836	Certificate of Analysis	Nov 14, 2022	I102602
B2302782	Certificate of Analysis	Nov 14, 2022	I102602
B2302774	Certificate of Analysis	Nov 14, 2022	I102602
H2222058	Certificate of Analysis	Jul 18, 2022	I102602
H2222059	Certificate of Analysis	Jul 18, 2022	I102602
H2222060	Certificate of Analysis	Jul 18, 2022	I102602
F1801026	Certificate of Analysis	Apr 22, 2022	I102602
F1801025	Certificate of Analysis	Apr 22, 2022	I102602
C2223340	Certificate of Analysis	Mar 08, 2022	I102602

Show more⌵

Chemical and Physical Properties

Solubility	Soluble in DMSO or DMF at approximately 20mg/ml. Sparingly soluble in aqueous buffers.
Sensitivity	heat sensitive

Safety and Hazards(GHS)

Pictogram(s)	GHS07
Signal	Warning
Hazard Statements	H302:Harmful if swallowed
Precautionary Statements	P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P317:IF SWALLOWED: Get medical help.
WGK Germany	3

Alternative Products

Citations of This Product

How to Cite Aladdin Scientific Products?

1. Jia Cui, Ziyi Zhang, Han Zhong, Tao Zhang. (2023) Phosphorylcholine-grafted graphene oxide loaded with irinotecan for potential oncology therapy. RSC Advances, 13 (41): (28642-28651). [PMID:37790105] [10.1039/D3RA04987F]
2. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo. (2023) Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels. JOURNAL OF CONTROLLED RELEASE, 360 (433). [PMID:37422124] [10.1016/j.jconrel.2023.07.003]
3. Tan Xi, Wang Chenhui, Zhou Hong, Zhang Shuting, Liu Xuhan, Yang Xiangliang, Liu Wei. (2023) Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma. JOURNAL OF NANOBIOTECHNOLOGY, 21 (1): (1-15). [PMID:37291573] [10.1186/s12951-023-01950-y]
4. Fei Wang, Xuyang Li, Xialin Hu, Wenya Zhuang, Jiewei Lai, Wenchao Wang, Xuanrong Sun, Hong Wang, Qingyong Li. (2022) Preparation and evaluation of camptothecin analogues-loaded lyophilization using Kolliphor® HS 15 as carrier. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 77 (103898). [PMID:] [10.1016/j.jddst.2022.103898]
5. Wang Yi, Wang Wenchao, Yu Endian, Zhuang Wenya, Sun Xuanrong, Wang Hong, Li Qingyong. (2022) Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability. JOURNAL OF NANOBIOTECHNOLOGY, 20 (1): (1-15). [PMID:36064403] [10.1186/s12951-022-01596-2]

References

1. Jia Cui, Ziyi Zhang, Han Zhong, Tao Zhang. (2023) Phosphorylcholine-grafted graphene oxide loaded with irinotecan for potential oncology therapy. RSC Advances, 13 (41): (28642-28651). [PMID:37790105] [10.1039/D3RA04987F]
2. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo. (2023) Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels. JOURNAL OF CONTROLLED RELEASE, 360 (433). [PMID:37422124] [10.1016/j.jconrel.2023.07.003]
3. Tan Xi, Wang Chenhui, Zhou Hong, Zhang Shuting, Liu Xuhan, Yang Xiangliang, Liu Wei. (2023) Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma. JOURNAL OF NANOBIOTECHNOLOGY, 21 (1): (1-15). [PMID:37291573] [10.1186/s12951-023-01950-y]
4. Fei Wang, Xuyang Li, Xialin Hu, Wenya Zhuang, Jiewei Lai, Wenchao Wang, Xuanrong Sun, Hong Wang, Qingyong Li. (2022) Preparation and evaluation of camptothecin analogues-loaded lyophilization using Kolliphor® HS 15 as carrier. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 77 (103898). [PMID:] [10.1016/j.jddst.2022.103898]
5. Wang Yi, Wang Wenchao, Yu Endian, Zhuang Wenya, Sun Xuanrong, Wang Hong, Li Qingyong. (2022) Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability. JOURNAL OF NANOBIOTECHNOLOGY, 20 (1): (1-15). [PMID:36064403] [10.1186/s12951-022-01596-2]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

Irinotecan hydrochloride - 98%, high purity , CAS No.100286-90-6

Basic Description

Associated Targets(Human)

Associated Targets(non-human)

Mechanisms of Action

Names and Identifiers

Certificates

Certificate of Analysis(COA)

Show more⌵

Chemical and Physical Properties

Safety and Hazards(GHS)

Related Documents

Alternative Products

Citations of This Product

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator